Tips and tricks of stoma closure - when and how

ESGO eAcademy, Martina Angeles Fite, 341078

Ghost ileostomy (indications, technique, experience)

ESGO eAcademy, Victor Lago, 341077

Stoma placement techniques

ESGO eAcademy, Andrei Pletnev, 341075

Frequency of pathogenic mutations and prognostic impact of germline gene panel testing in patients with primary epithelial ovarian cancer

ESGO eAcademy, Beyhan Ataseven, 343799

Avelumab combined with pegylated liposomal doxorubicin in platinum-resistant/refractory ovarian cancer: biomarker analyses from JAVELIN Ovarian 200

ESGO eAcademy, Eric Lauraine, 343808

Partial molar pregnancy with a coexisting fetus; Case series and review of the literature

ESGO eAcademy, Leonora Coopmans, 343805

Lower-limb lymphedema after sentinel lymph node biopsy in cervical cancer patients

ESGO eAcademy, Renata Poncova, 343798

Incidence of lymph node metastasis in cervical carcinoma with ≤5 mm depth of invasion and >7 mm horizontal spread

ESGO eAcademy, Laure Nicolai, 343800

Can a cone biopsy predict nodal status in  early cervical cancer?

ESGO eAcademy, Enrique Maria Chacon Cruz, 343801

Ovarian cancer onset across different BRCA mutation type

ESGO eAcademy, Claudia Marchetti, 343802

Is the serous tubal intraepithelial carcinoma to blame for peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy?

ESGO eAcademy, Miranda P. Steenbeek, 343803

Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA Trial

ESGO eAcademy, Dana Chase, 343804

The annual recurrence risk model for tailored surveillance strategy in cervical cancer patients

ESGO eAcademy, David Cibula, 343807

Screening in the era of HPV vaccination: what changes to expect

ESGO eAcademy, Peter David Sasieni Sasieni, 341064

Prophylactic HPV vaccination in women with previous cervical disease and global impact

ESGO eAcademy, Maria Kyrgiou, 341063

What is the best combinatorial partner to enhance benefit from PDL1i in cervical cancer?

ESGO eAcademy, Alexandra Leary, 350674

Combinations to reverse resistance to PARPi in ovarian cancer

ESGO eAcademy, Amit Oza, 343793

New trends in the treatment of vulvar squamous cell cancer

ESGO eAcademy, Maaike Oonk, 343789

Non-epithelial vulvar malignancies and treatment options

ESGO eAcademy, Elena Ulrikh, 343790

What is the best combinatorial partner to enhance benefit from PDL1i in cervical cancer?

ESGO eAcademy, Alexandra Leary, 343792

Combinatorial approaches in endometrial cancer

ESGO eAcademy, Domenica Lorusso, 343794

Combining targeted agents - Discussion

ESGO eAcademy, Faculty / Presenters, 343795

Prophylactic HPV vaccines: evidence and challenges

ESGO eAcademy, Elmar Joura, 341062

Presentation of the ESGO-ISUOG-IOTA-ESGE Consensus statement on preoperative diagnosis of ovarian masses

ESGO eAcademy, Christina Fotopoulou, 341052

Overview of staging imaging modalities and an assessment of tumour resectability

ESGO eAcademy, Daniela Fischerova, 341051

Mullerian Adenosarcomas of the Female Genital Tract

ESGO eAcademy, Michael Friedlander, 343784

ONLINE Scientific session 3: ESGO-GCIG rare tumours project: Algorithms to guide management

ESGO eAcademy, Faculty / Presenters, 341042

Overview of the diagnosis of ovarian masses

ESGO eAcademy, Dirk Timmerman, 341050

Small Cell Carcinoma of the Cervix (SCCC)

ESGO eAcademy, Olesya Solheim, 343787

Borderline Ovarian Tumours

ESGO eAcademy, Christianne Lok, 343786

Glandular carcinoma of cervix

ESGO eAcademy, Marie Plante, 343785

Non squamous vulvar and vaginal carcinoma

ESGO eAcademy, Mario Leitao Jr., 343778

Clear cell cervical and uterine carcinoma

ESGO eAcademy, Mary McCormack, 343779

Carcinoid ovarian tumour

ESGO eAcademy, EVA GOMEZ GARCIA, 343780

Low grade endometrial stromal sarcoma

ESGO eAcademy, Frederic Amant, 343781

High grade endometrial and undifferentiated sarcoma

ESGO eAcademy, Patricia Pautier, 343782

Papillary serous carcinoma of uterus

ESGO eAcademy, Bradley J. Monk, 343783

Financial toxicity of PARP inhibitor maintenance: a US and European perspective - Q&A

ESGO eAcademy, Faculty / Presenters, 341026

Inguino-femoral lymphadenectomy

ESGO eAcademy, Christina Pappa, 341039

Extra-peritoneal left pelvic lymphadenectomy

ESGO eAcademy, Agnieszka Rychlik, 341038

EU PARP financial toxicity

ESGO eAcademy, Richard Sullivan, 341025

Video abstract 2 - ID 640: Raising adequate vaginal margins during colpotomy for cervical cancer

ESGO eAcademy, Shylasree TS, 341037

Video abstract 1 - ID 357: Step by step laparoscopic hysterectomy with pelvic and para-aortic lymphadenectomy. Anatomical landmarks

ESGO eAcademy, Krzysztof Nowak, 341036

Laparoscopic ovarian transposition in 10 steps

ESGO eAcademy, Nicolo Bizzarri, 341035

The unique challenges of oral cancer therapy costs in gynecologic oncology: a perspective from the United States

ESGO eAcademy, Margaret Liang, 341024

Laparoscopic sentinel lymph node mapping - different techniques Tc, Blue, ICG and resection of parametrial lymphatic channel

ESGO eAcademy, Michael Halaska, 341034

ONLINE Scientific session 2: Financial toxicity of PARP inhibitor maintenance: a US and European perspective

ESGO eAcademy, Faculty / Presenters, 341019

Avelumab in patients with gestational trophoblastic tumors resistant to polychemotherapy: Efficacy outcomes of cohort B of TROPHIMMUN phase II trial.

ESGO eAcademy, Benoit You, 343771

Diagnostic accuracy of sentinel node biopsy in non-endometrioid, high-grade and/or deep myoinvasive endometrial cancer (TRSGO-SLN-006)

ESGO eAcademy, Duygu Altõn, 343772

Comprehensive genome-wide analysis of non-invasive test data allows accurate cancer prediction: a retrospective analysis of over 85.000 pregnancies

ESGO eAcademy, Liesbeth Lenaerts, 343773

Sensitivity and false negativity of SLN frozen section histological evaluation in the Sentix trial (CEEGOG-CX01; ENGOT-CX2; NCT02494063)

ESGO eAcademy, Roman Kocian, 343774

Financial toxicity of gynecologic cancer treatment

ESGO eAcademy, Emeline Aviki, 341023

Minor and plastic reconstructive procedures in vulvar malignant and premalignant lesions - Q&A

ESGO eAcademy, Faculty / Presenters, 341014

What we have done good, what we have done wrong

ESGO eAcademy, Francesco Raspagliesi, 341006

Neovagina-formation by Vertical Rectus Abdominis Myocutaneous (VRAM) flap / Gracilis flap

ESGO eAcademy, Ignacio Zapardiel, 341013

Gynaecological oncology research in the COVID context

ESGO eAcademy, Luis Chiva, 341005

Fertility sparing surgery in cervical cancer patients outside controlled trials – a multicenter retrospective cohort trial (CEEGOG Cx-03; ENGOT-CX14)

ESGO eAcademy, Jiri Slama, 343768

STELLA-2 trial: Surgical complications comparing extraperitoneal vs transperitoneal MIS aortic staging in early stage ovarian and endometrial cancer

ESGO eAcademy, Vicente Bebia Conesa, 343766

Prognostic relevance of the molecular endometrial cancer classification among patients staged by lymphadenectomy and/or without adjuvant treatment

ESGO eAcademy, Alicia Leon-Castillo, 343764

Molecular subclassification of vulvar squamous cell carcinoma: prognostic significance and reproducibility

ESGO eAcademy, Emily F. Thompson, 343760

Impact of COVID-19 on gynaecological cancer outcomes

ESGO eAcademy, Sudha Sundar, 341004

ONLINE ENYGO video session: Minor and plastic reconstructive procedures in vulvar malignant and premalignant lesions

ESGO eAcademy, Faculty / Presenters, 341009

Laser skinning vulvectomy

ESGO eAcademy, Michael Halaska, 341012

State of the art 14: Management of medical complications related to new therapies - Q&A

ESGO eAcademy, Faculty / Presenters, 340996

Management of PARPi, ADC and other targeted-therapy-related side effects

ESGO eAcademy, Susana Banerjee, 340995

Natural history of HPV infection with differing subtypes; an epidemiological perspective

ESGO eAcademy, Karin Sundström, 340988

Utilising the cervical microbiome and epigenome in order to predict women’s cancers risks

ESGO eAcademy, Martin Widschwendter, 340987

Best Oral session 3: Ovarian cancer - Q&A

ESGO eAcademy, Faculty / Presenters, 343758

Can pharmacogenetics predict chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy?

ESGO eAcademy, Katie Dorr, 343755

Analysis of patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer in the phase 3 ARIEL3 study

ESGO eAcademy, Jonathan Ledermann, 343754

Surgical outcome as prognostic factor in different histologic subtypes of ovarian carcinoma- analysis of 7 phase III trials by AGO Studygroup + ENGOT

ESGO eAcademy, Florian Heitz, 343753

HPV natural infection, its clearance and vaginal flora - Q&A

ESGO eAcademy, Faculty / Presenters, 343749

Management of check-point inhibitor-related side effects

ESGO eAcademy, Antonio Gonzalez Martin, 340994

Cervical pre-invasive and invasive disease, HPV clearance and microbiota

ESGO eAcademy, Murat Gultekin, 340986

Primary Imiquimod Treatment versus Surgery for Vulvar Intraepithelial Neoplasia - PITVIN study. A Randomized Clinical Trial

ESGO eAcademy, Gerda Trutnovsky, 346111

QPOLE: multiplex qPCR hotspot testing of pathogenic POLE mutations: a rapid, simple and reliable approach for POLE assessment in endometrial cancer

ESGO eAcademy, Anne-Sophie van den Heerik, 346113

A randomised phase II study of combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer. NSGO/ENGOT-EN1/FANDANGO

ESGO eAcademy, Faculty / Presenters, 346115

The impact of intensive follow-up on health-related quality of life and costs in endometrial cancer patients: data from the TOTEM trial NCT00916708

ESGO eAcademy, Paolo Zola, 346117

State of the art 12: Prevention strategies in high risk women - Q&A

ESGO eAcademy, Faculty / Presenters, 340968

Role of early salpingectomy and delayed oophorectomy in high-risk women

ESGO eAcademy, Joanne A. De Hullu, 340967